drugset
Drugs / cH8/1N1 LAIV
last change Aug 2019 re-read 3 minutes ago

cH8/1N1 LAIV

Vaccine

Developed for
influenza
Investigated by
Children's Hospital Medical Center, Cincinnati · Duke University · GlaxoSmithKline · Icahn School of Medicine at Mount Sinai · PATH · The Emmes Company, LLC

Trials 1

today NCT03300050 · Ph 1
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03300050 Oct 2017 → Apr 2018 influenza PATH Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as cH8/1N1 LAIV ClinicalTrials.gov intervention name — accepted as the source's own label NCT03300050 ↗
Modality Vaccine “Live-attenuated influenza virus vaccine (LAIV) expressing chimeric hemagglutinin (HA)” NCT03300050 ↗
Route Intranasal “Administered intranasally as drops” NCT03300050 ↗